Questions: Monoamine Neurotransmitter Synthesis and Catabolism

Question 1

A patient taking an MAOI antidepressant eats aged cheese, which is high in tyramine. What is the likely consequence and why?

• A. The tyramine is converted to dopamine in the brain, amplifying the antidepressant effect
• B. Nothing unusual — MAO inhibitors block monoamine synthesis, not tyramine metabolism
• C. Tyramine that would normally be degraded by MAO in the gut accumulates and can trigger a dangerous hypertensive crisis
• D. Tyramine competes with serotonin at the synapse, partially reversing the antidepressant's effect

Answer: (C)

MAO in the gut wall normally breaks down dietary tyramine before it can enter the bloodstream. When MAO is inhibited, tyramine accumulates and enters circulation, where it triggers norepinephrine release from sympathetic terminals, causing severe vasoconstriction and hypertensive crisis. This is a real medical emergency. The question illustrates a key point: MAO doesn't just degrade neurotransmitters in the brain — it also inactivates dietary amines in peripheral tissues, and inhibiting it has consequences throughout the body.

Question 2

A researcher blocks the serotonin transporter (SERT) with an SSRI. By what primary mechanism does synaptic serotonin increase?

• A. Tryptophan hydroxylase accelerates serotonin synthesis in response to reduced reuptake
• B. COMT is inhibited secondarily, reducing serotonin breakdown in the postsynaptic neuron
• C. Serotonin released into the synapse remains there longer because its reuptake into the presynaptic terminal is blocked
• D. MAO activity declines because less serotonin enters the presynaptic terminal where MAO is located

Answer: (C)

The dominant route for clearing synaptic serotonin is reuptake — the serotonin transporter (SERT) pulls released serotonin back into the presynaptic terminal. SSRIs block SERT, so serotonin lingers in the synapse longer and has more opportunity to bind postsynaptic receptors. Synthesis rate and enzymatic degradation are not the primary targets. Option D has a subtle logic to it (less serotonin in the terminal could mean less MAO substrate) but this is a minor secondary effect, not the primary mechanism.

Question 3

The rate-limiting step in dopamine synthesis is the conversion of L-DOPA to dopamine by DOPA decarboxylase.

• T. True
• F. False

Answer: False

The rate-limiting step is the FIRST reaction: tyrosine hydroxylase converting tyrosine to L-DOPA. This is the step that controls how much dopamine the neuron can produce. DOPA decarboxylase (which converts L-DOPA to dopamine) is fast and rarely rate-limiting. This distinction has direct clinical relevance: L-DOPA supplements work in Parkinson's disease precisely because supplying L-DOPA bypasses the deficient tyrosine hydroxylase step in the dopaminergic neurons of the substantia nigra.

Question 4

Individuals with the COMT Val/Val genotype tend to have lower prefrontal dopamine levels than Met/Met individuals, which can impair working memory.

• T. True
• F. False

Answer: True

The Val variant of COMT degrades dopamine roughly four times faster than the Met variant, resulting in lower steady-state dopamine levels in the prefrontal cortex. Since prefrontal dopamine is critical for working memory, Val homozygotes tend to show worse working memory performance under normal conditions. Paradoxically, they may also show more resilience to certain stress-induced dopamine surges, illustrating the 'warrior-worrier' tradeoff associated with this polymorphism.

Question 5

Why do MAO inhibitors require tyramine dietary restrictions while SSRIs do not? What does this reveal about the difference between these two pharmacological mechanisms?

Model answer: MAOIs block the enzyme that degrades tyramine in the gut wall and periphery, allowing dietary tyramine to accumulate and trigger dangerous sympathetic activation. SSRIs only block reuptake at serotonergic synapses in the nervous system and have no effect on MAO or peripheral tyramine metabolism, so no dietary restriction is needed. This illustrates that the two drug classes target entirely different steps in the monoamine cycle: MAOIs affect enzymatic degradation (a metabolic step), while SSRIs affect the transporter (a reuptake step).

The distinction matters clinically: reuptake blockers are synapse-specific and have minimal peripheral effects because the transporter is expressed mainly at serotonergic terminals. MAO, by contrast, is expressed in peripheral tissues throughout the body — gut, liver, platelets — where it serves as a general amine clearance system. Inhibiting it therefore affects all amines, including dietary ones, not just monoamine neurotransmitters in the brain.